Relaxin-2 reduces liver steatosis in mice with high-fat diet (HFD)-induced non-alcoholic fatty liver disease with simple steatosis or methionine-choline-deficient (MCD) diet-induced non-alcoholic steatohepatitis by activating the eNOS/NO pathway. Additionally, relaxin-2 improves insulin resistance and obesity in HFD mice. In MCD mice, relaxin-2 further attenuates hepatic inflammation and fibrosis with reduction in levels of hepatocyte apoptosis and hepatic stellate cell activation.
- Kuei-Chuan Lee
- Yun-Cheng Hsieh
- Han-Chieh Lin
